Main: +45 31 10 91 91
Fax: +45 77 31 15 09
CVR/VAT no. 31348854
Ordering: +45 29 13 42 24
Immudex is a fast-growing biotech company, providing solutions for T-cell immune monitoring within immunotherapy, transplantation, infectious disease, and autoimmunity. Based on our proprietary Dextramer technology, we develop and market research reagents and diagnostic assays, enabling researchers, developers, and clinicians to measure disease-specific T-cell responses.
You will be leading our new Manufacturing Development unit and be in close contact with our R&D, QC, and Production departments. You will report to the Production Director. Location: Virum, Denmark.
You will work cross-functionally with colleagues from other departments and your own growing team while securing project milestones are executed timely. Knowledge of expression and purification of proteins, such as MHC molecules, will be a strong asset.
Your primary tasks will be to:
We expect that you have an academic background within engineering or natural sciences, preferably combined with a PhD within biotechnology, cell biology, or similar, and at least 5 years of experience with manufacturing development. Furthermore, we value:
You must be able to build strong and high performing teams based upon our core values of trust, commitment, and quality. Therefore, we expect you can demonstrate:
Immudex offers a dynamic workplace in a fast-growing company where we have an informal work environment characterized by dedicated employees with a desire to make a difference.
We process applications on a continuous basis which is why we encourage you to send your application and CV as soon as possible to email@example.com
If you have any questions about the position, please contact:
Production Director, firstname.lastname@example.org, mob. +45 6065 0245
Based in Copenhagen, Denmark, with North American operations based in Fairfax, Virginia, Immudex manufactures MHC Dextramer® for the detection of antigen-specific T cells. Under an
agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer
Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency
panel services worldwide.
Immudex' MHC Dextramer® products are utilized for the quantification or sorting of antigen-specific
T cells in life science research, in vitro diagnostics, as well as the development of
immunotherapeutics and vaccines. The primary focus is research-use-only products for the
immune monitoring of immunotherapy development and monitoring of CMV cellular immunity in
transplant and other immune-deficient patients. In Europe, the CE marked Dextramer CMV Kit is
approved for in vitro diagnostic use for the quantification of CMV-specific T cells.
USA FDA 510(k) clearance for the CMV kit was granted March 2017. GMP Grade reagents are
Our state-of-the-art dCODE Dextramer reagents enable massive multiplexing of antigen-specific Tcell
detection. Detection of over 1000 CD8+ T-cell specificities from a single blood sample has